Mevalonate pyrophosphate decarboxylase (MPD) is considered to be a cytosolic protein. Recently, other groups reported that MPD is mostly located in the peroxisomes. In this study, we examined whether the expression of MPD in mice depends on the proliferation of peroxisomes, and whether MPD is predominantly located in the peroxisomes or the cytosol of mice. No increase in the protein level of MPD was observed in the crude extract of the livers of mice administered with peroxisome proliferative drugs. The result suggests that the expression of MPD is independent of the proliferation of peroxisomes, and may be maintained via a specific regulatory mechanism, different from the regulation of the expression of peroxisome proliferator-activated receptor alpha. When the subcellular distribution of MPD in mouse melanoma (B16F10) cells was examined by cell fractionation, MPD was detected in the cytosol of B16F10 cells, but not in the peroxisomes. In permeabilized B16F10 cells treated with digitonin, which lack cytosolic enzymes, 80% and 20% of MPD, 75% and 25% of lactate dehydrogenase, or 2% and 98% of catalase, existed in the medium and in the cell, respectively. From these results, it indicated that MPD was predominantly located in the cytosol and did not exist in the peroxisomes of B16F10 cells.
One of the first steps in the biosynthesis of cholesterol from acetic acid is the catalyzing by mevalonate pyrophosphate decarboxylase (MPD). This decarboxylase catalyzes a bimolecular reaction between mevalonate pyrophosphate and ATP to form isopentenyl pyrophosphate, inorganic phosphate, ADP, and CO 2 . The enzyme has been purified from various sources, including yeast, 1, 2) latex of Hevea brasiliensis, 3) pig liver, 4, 5) rat liver, [6] [7] [8] mouse liver, 9) and chicken liver. 10) Toth and Huwyler reported the cDNA sequences of MPD from human liver and yeast. 11) The recombinant human enzyme is a homodimer of a 43-kDa subunit with 400 amino acids.
MPD is found in the 100000ϫg supernatant fraction of tissue and has been considered a cytosolic protein. Recently , it has been demonstrated by other groups that peroxisomes contain a number of enzymes involved in cholesterol biosynthesis, which were previously considered to be cytosolic, or located exclusively in the endoplasmic reticulum (ER). Peroxisomes have been shown to contain acetoacetyl-CoA thiolase, 12, 13) 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) synthase, 14) HMG-CoA reductase, 15, 16) mevalonate kinase (MVK), 17, 18) phosphomevalonate kinase (PMVK), 19) MPD, 19) isopentenyl pyrophosphate isomerase (IPPase), 20) and farnesyl pyrophosphate synthase (FPPase). 21) Recent data have also shown that the activity of some enzymes, including MVK and FPPase, is significantly reduced in liver tissue obtained from patients with peroxisome-deficient diseases (Zellweger syndrome and neonatal adrenoleukodystrophy), thus indicating a peroxisomal localization of these enzymes. 21) Hogenboom et al. reported that the activity and protein levels of selected enzymes involved in cholesterol biosynthesis, were at least as high in the peroxisome-deficient Zellweger mice as in control mice, indicating that the mislocalization of enzymes to the cytosol does not lead to decreased activity or the degradation of these enzymes. 22) They also reported that the previously reported deficiencies of MVK and PMVK activity in liver from human Zellweger patients reflects the bad condition of the liver, rather than a mislocalization to the cytosol. 22) From these data, the relationship between peroxisome proliferation and the enzyme involved in cholesterol biosynthesis of mice remains unclear.
Biardi and Krisans reported that MPD was mainly located in peroxisomes, since the activity of MPD was the same in extracts prepared from intact cells and selectively permeabilized cells, which lack cytosolic enzymes. 19) We previously reported that MPD existed in peroxisomes of rat liver, fed on a diet containing 5% cholestyramine and 0.1% pravastatin (CP diet; a CP diet induced MPD in rat liver) by cell fractionation. 23) We also reported that MPD was predominantly located in the cytosol of rat hepatocytes or normal rat kidney (NRK) cells, since in permeabilized rat hepatocytes or NRK cells treated with digitonin, which lack cytosolic enzymes, MPD was mainly present in the medium. 24) Therefore, it was suggested that the difference in distribution of MPD between our previous results (rat hepatocytes or NRK cells) and other reports (monkey kidney cells; CV-1 cells) may be due to cell type, since our previous findings are somewhat different from the observations reported by Biardi and Krisans in permeabilized nonhepatic CV-1 cells.
In the present study, we examined whether the expression of MPD in mice depends on the proliferation of peroxisomes, and the subcellular distribution of MPD in mouse melanoma (B16F10) cells.
MATERIALS AND METHODS
Materials B16F10 cells were kindly provided by Dr. J. T. August (Johns Hopkins University). Clofibrate was kindly provided by Yamanouchi. Rabbit anti-catalase antibody was purchased from Polysciences, Inc. All other chemicals were of reagent grade and purchased from commercial sources.
Animals Male ddy mice (8 weeks old) were used to examine the effect of peroxisome proliferative drugs. The mice were fed on powdered chow, with or without 0.5% clofibrate.
Marker Enzyme The activity of catalase (peroxisomal marker) was measured according to a previously reported method.
25) The activity of lactate dehydrogenase (LDH), a cytosol marker, was measured according to the method of Abei.
26)
Preparation of Antibody Polyclonal antiserum raised against the lysosome-associated membrane glycoprotein (lamp-2, a lysosome marker), as described by Akasaki et al., 27) was used. Polyclonal antiserum was raised against cathepsin B (lysosome marker), as described by Yokota et al. 28) Polyclonal antiserum raised against the phenobarbitalinducible cytochrome P-450 (CYP2B1, a microsome marker), as described by Tsuji et al., 29) was used. MPD was purified from rat liver, as described by Michihara et al., 8) and polyclonal antiserum raised against the MPD was used.
Purification of MPD Antibody The purification of MPD antibody was carried out as described by Michihara et al. 24) When 60 mg of crude extract of mouse liver was subjected to sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE), followed by immunoblot analysis using the purified MPD antibody, only a 46 kDa band was detected. An excess of rabbit anti-rat MPD antibody deleted approximately 80% of the MPD activity in the crude extract of mouse liver.
9)
Cultured Melanoma Cell Line B16F10 cells (3ϫ10 6 ) were diluted with Dallbeco's Eagle essential medium (DMEM) containing 10% fetal calf serum (FCS) and then incubated in humidified air containing 5% CO 2 at 37°C for 24 h.
Cultured Normal Rat Kidney (NRK) Cell Line NRK cells (3ϫ10 6 ) were diluted with DMEM containing 10% FCS, and then incubated in humidified air containing 5% CO 2 at 37°C for 24 h.
Cell Permeabilization B16F10 cells incubated on 60-mm dishes were washed several times in cold Hanks' buffer. On the day of the experiment, the medium was aspirated from the culture dishes and cells were then washed twice with ice-cold KH buffer [50 mM phosphate buffer (pH 7.2), 110 mM KOAc]. The cells were transferred to ice and then incubated for various times in 1.5 ml of KHM buffer containing 40 mg/ml of digitonin, 20 mM phosphate buffer (pH 7.2), 110 mM KOAc, and 2 mM MgOAc. The digitonin solution was retained for marker enzyme or protein assay and immunoblotting. After digitonin treatment and washing, 1.5 ml of PBS containing 0.5 mM PMSF, 1% Triton X-100, 10 mM mercaptoethanol, 1 mM EDTA, and protease inhibitors (1 mM leupeptin, 1 mM pepstatin A, 1 mM chymostatin, and 1 mM antipain), was added to the cells, and the cells were then scraped off using a rubber policeman. The solution of B16F10 cells was homogenized with 20 strokes in a Teflon homogenizer.
After centrifugation for 5 min at 1000ϫg, the supernatant solutions were used for marker enzyme or protein assay and immunoblotting. Nonpermeabilized cells were treated with KHM buffer without digitonin, and processed in the same way as the digitonin-treated cells. The amount of protein or enzyme activity retained in the nonpermeabilized cells was taken to be 100%.
Cell Fractionation Cell fractionation was carried out according to Michihara et al. 23) B16F10 cells (1 g) were washed with 100 mM sodium phosphate (pH 7.0) containing 10 mM mercaptoethanol and 1 mM EDTA (buffer A), and then homogenized with 3 volumes of ice-cold buffer A containing 0.5 mM PMSF and protease inhibitors (1 mM leupeptin, 1 mM pepstatin A, 1 mM chymostatin, and 1 mM antipain) (buffer B) using a Nitrogen capitation. The homogenate was centrifuged at 1000ϫg for 10 min. The supernatant was saved, then the pellet was resuspended, homogenized, and centrifuged again at 1000ϫg for 10 min. The two supernatants were then combined and centrifuged at 7000ϫg for 6 min. The supernatant was then centrifuged at 20000ϫg for 20 min.
(i) The supernatant contained cytosol and microsomes.
(ii) The pellet contained peroxisomal-enriched fraction.
The supernatant of (i) was centrifuged at 105000ϫg for 1 h. The supernatant contained cytosolic proteins. Therefore, this supernatant was designated the cytosol fraction (cytosol) in this study.
After the pellet of (ii), containing peroxisomal-enriched fraction, was resuspended with 3 ml of centrifuge buffer (10 mM glycyl-glycine, 1 mM EDTA, 0.5 mM PMSF, and protease inhibitors), the peroxisomal-enriched fraction was layered on top of sucrose gradient solutions (7 ml of 23.2%, 8 ml of 37.4%, 10 ml of 45.8%, and 5 ml of 53.9%) containing 10 mM glycyl-glycine, and then centrifuged at 23000 rpm for 2 h using a Beckman SW 28 rotor. Twenty-three fractions were collected from the top to the bottom. The specific activity of catalase in fraction 19 was approximately 40 times higher than that in the B16F10 cell homogenate. Therefore, fraction 19 was designated the peroxisomal fraction (peroxisomes) in this study. These results were similar to the results obtained in the cell fraction of rat liver.
23)
Gel Electrophoresis SDS-PAGE was performed on 10% slab gels according to the method of Laemmli.
30)
Immunoblot Procedures Proteins in SDS-slab gel were transferred to a nylon membrane (NEN) by electrophoresis, using a modified version of the procedure of Towbin et al. 31) The positive bands were visualized using ECL Western blotting detection kits (Amersham Pharmacia, Amersham, U.K.) that contained a sensitive chemiluminescent substrate for horseradish peroxidase.
Protein Determination Proteins were determined by the method of Lowry et al., 32) using bovine serum albumin as the standard.
RESULTS AND DISCUSSION
The Change in the Protein Level of MPD in the Crude Extract of the Livers of Mice Administered with Peroxisome Proliferative Drugs In general, clofibrate is known to be a peroxisome proliferative drug, and to cause an increase in liver weight and catalase levels. Therefore, liver weight and the amount of catalase were measured as markers of peroxisome proliferation. The liver weight had increased 3-fold by the administration of clofibrate for 15 d, as compared with the corresponding value in mice fed normal chow for 15 d (Fig. 1A) . The results of the immunoblot analysis performed with anti-catalase antibody, using the livers of mice fed with peroxisome proliferative drugs or normal chow, are shown in Fig. 1B . The amount of catalase had increased 4-fold by clofibrate administration for 15 d, as compared with the corresponding values in mice fed normal chow for 15 d. These data indicate that peroxisomes were significantly increased by the administration of peroxisome proliferative drugs for 15 d. To establish whether the expres-sion of MPD depends on the proliferation of peroxisomes, we examined the increase of MPD in crude liver extracts after the administration of peroxisome proliferative drugs. There was no difference in the amount of MPD in the crude extracts prepared from mice administered with clofibrate for 15 d and mice fed normal chow for the same period (Fig.  1C) . The result indicates that the total amount of MPD was not increased by peroxisome proliferative drugs. Peroxisome proliferative drugs, such as clofibrate, have been shown to activate peroxisome proliferator-activated receptor alpha (PPARa), a member of the steroid nuclear receptor superfamily. Hogenboom et al. reported that the activities and protein levels of MPD were at least as high in peroxisome-deficient Zellweger mice as in control mice. 22) Based on these facts, we considered that the expression of MPD was independent of the proliferation or deficiency of peroxisomes, and may be maintained by a specific regulatory mechanism different from the regulation of expression by PPARa.
Cell Fractionation of B16F10 Cells When peroxisomes and cytosol in intact B16F10 cells were isolated on sucrose gradients, as described in Materials and Methods, catalase was detected (Fig. 2A) . MPD was detected in the cytosol, but not in the peroxisomes (Fig. 2B) . The signal of the catalase or MPD in each fraction was measured by Gel-Pro analyzer and an arbitrary unit (arbitrary value of the signal of the catalase or MPD/protein (mg) in each fraction) was estimated. The specific activity of LDH was also measured in each fraction. The arbitrary unit of the catalase, or the specific activity of LDH in the peroxisomes, were 40 times or 1.5 times higher than that in the homogenate. The specific activity of LDH, or the arbitrary unit of MPD or catalase in the cytosol, were 4.5 times, 4.5 times or 1.8 times higher than that in the homogenate. It is highly possible that MPD was predominantly located in the cytosol, since the relative enrichment of LDH (4.5) in the cytosol was similer to that of MPD (4.5). Also, the release of the catalase was indicated from peroxisomes to cytosol, because the protein in the matrix of the peroxisomes was released with the rupture of the peroxisomes during cell fractionation. MVK and FPPase were involved in cholesterol biosynthesis predominantly located in the peroxisomes. 17, 21) However, when the subcellular location of these proteins were determined by immunoblotting individual gradient fractions, they contained less peroxisomes than cytosol. 17, 21) Therefore, MPD in the peroxisomes may be released with a rupture of the peroxisomes during cell fractionation. However, it is highly possible that MPD does not exist in the peroxisomes, since MPD was not detected in the peroxisomes.
Selective Permeabilization of the Plasma Membrane, and Release of Cytosolic Components in B16F10 Cells
In order to further study the subcellular localization of MPD, we selected to use permeabilized cells, which retain their organelle integrity yet lack cytosolic components. Digitonin treatment of cells has been reported to permeabilize the plasma membrane reversibly, leaving subcellular organelles intact. Therefore, we used digitonin permeabilization of B16F10 cells to characterize the main subcellular distribution of MPD. The time course of the release of cellular enzymes, LDH, catalase, and total cellular protein, is shown in Fig. 3 . Most protein release from the permeabilized cells occurred within 10 min and was not changed after 10 min of treatment. At this time, 75% of the activity of LDH, and about 30% of total cellular protein, were released. However, catalase activity was almost all retained in the permeabilized cells, indicating that the peroxisomes remained intact. Based on the kinetic studies, we chose a 10-min permeabilization period in which cellular protein loss plateaued (Fig. 3) .
To determine whether only the plasma membrane was disrupted and the cell organelles remained intact, we determined various marker enzyme activities or protein in both permeabilized and intact cells. As shown in Fig. 4 , total cellular protein, LDH, and catalase activities in the medium after digitonin treatment were 30%, 75%, and 2%, respectively. Lamp-2, cathepsin B (data not shown), and CYP2B1, were not released in the medium from the permeabilized cells, and were retained in amounts equal to those in the intact cells. These results demonstrated that the plasma membrane of the B16F10 cells could be selectively permeabilized with low concentrations of digitonin, resulting in the release of cytosolic proteins, while maintaining organelle integrity.
Localization of MPD in Intact and Permeabilized B16F10 Cells To determine whether MPD was mainly present in the cytosol or peroxisomes (or other organelles), the amount of MPD protein was examined in the cell fraction of nonpermeabilized and permeabilized cells, or the medium fraction, using immunoblot analysis. As shown in Fig. 5 , the nonpermeabilized cells retained most of the MPD protein, while MPD protein from the permeabilized cells was found At different incubation times, samples were collected and analyzed for protein (᭹) and enzymatic activities of LDH (᭡) and catalase (), as described in Materials and Methods. Nonpermeabilized cells were treated with buffer without digitonin, and samples were processed similarly. After 35 min, the incubation buffers were removed, cell extracts were prepared, and enzyme activity and protein were determined. The amount of protein or enzyme activity retained in cells from the control dishes was defined as 100%. The values are expressed as the percentage of total protein or enzyme activity remaining in the nonpermeabilized cell. Data are the means of six identical experiments, and each varies within 5%. Protein (total protein and CYP2B1) or activity (LDH and catalase) in the medium (M, ᮀ), and protein or activity remaining in the cells (C, ), were measured using nonpermeabilized (NP) or permeabilized (P) cells, as described in Materials and Methods. Total protein was measured by the method of Lowry. Signals of the CYP2B1 were quantified using a Gel-Pro analyzer. The amount of protein or enzyme activity retained in the nonpermeabilized cells was taken as 100%. Data are the means of six identical experiments, and each varies within 10%. A: B16F10 cells were incubated in KHM buffer in the presence (P) or absence (NP) of digitonin for 5 min at 4°C, and the cells (C; 10 ml) and the medium (M; 10 ml) were analyzed by immunoblotting. B: Signals of A were quantified using a Gel-Pro analyzer. C: Rat hepatocytes were incubated in KHM buffer in the presence of digitonin for various times at 4°C, and the cells (10 ml) were analyzed by immunoblotting. Signals of the band were quantified using a Gel-Pro analyzer. The amount of MPD retained in the nonpermeabilized cells was taken as 100%. Data are the means of three identical experiments, and each varies within 5%. mainly in the medium. Eighty percent of the MPD protein was released after a 5-min incubation, and 20% was retained after a 20-min permeabilization. These results suggest that MPD was predominantly located in the cytosol of the B16F10 cells. Also, it is highly possible that MPD does not exists in the peroxisomes, since 20% or 25% of MPD or LDH was retained in cells containing peroxisomes after the 20-min permeabilization, respectively. In the present study (experiment of digitonin and cell fractionation), we concluded that MPD was predominantly located in the cytosol (80% or more), and did not exist in the peroxisomes of the B16F10 cells.
Comparison of Subcellular Distribution in B16F10 and NRK Cells Preincubated with or without FCS Biardi and Krisans reported that MPD was mainly located in peroxisomes, using cells transferred to media containing lipoprotein-deficient serum 24 h prior to the experiment. The data showed that the activity of MPD was the same in extracts prepared from intact cells and selectively permeabilized cells, which lacked cytosolic enzymes. 19) We previously reported that MPD was predominantly located in the cytosol using rat hepatocytes and NRK cells incubated to media containing 10% FCS prior to the experiment. The data showed that MPD was present mainly in the medium of permeabilized rat hepatocytes or NRK cells treated with digitonin. 24) In this study, as shown in Fig. 5 , we found that MPD was predominantly located in the cytosol using B16F10 cells incubated with media containing 10% FCS prior to the experiment. To establish whether the change of distribution of MPD was caused by cholesterol-deficient serum, the subcellular distribution of MPD in B16F10 and NRK cells, transferred to medium in the presence or absence of 10% FCS 24 h prior to the experiment, was examined. In B16F10 and NRK cells transferred to medium without 10% FCS, nonpermeabilized cells retained most of the MPD protein, while MPD protein from permeabilized cells was found mainly in the medium (Fig. 6 ). Ninety percent of the MPD protein was released after a 5-min incubation, and 10% of the MPD protein was retained after a 20-min permeabilization. From these data, it was found that the release of MPD in medium without FCS was similar to that in medium with FCS. These results suggested that MPD was predominantly located in the cytosol, and the distribution of MPD was not related to the cell type or experiment condition.
Peroxisomes have been shown to contain acetoacetyl-CoA thiolase, 12, 13) HMG-CoA synthase, 14) HMG-CoA reductase, 15, 16) MVK, 17, 18) PMVK, 19) MPD, 19) IPPase, 20) and FPPase, 21) whereas squalene synthase is predominantly located in the ER. 33) Recently, the enzymes involved in cholesterol synthesis have been shown to contain a peroxisomal targeting signal (PTS-1 ((S/A/C)(K/H/R)(L/M)) found at the extreme carboxy terminal of most peroxisomal proteins, and PTS-2 ((R/K)(L/V/I)(X 5 )(H/Q)(L/A)) found within the amino terminal region of a smaller subset of peroxisomal proteins). 34) A peroxisomal targeting signal of MVK and PMVK was identified as a PTS-2(KV(X 5 )HA) and -1(SRL), respectively. Peroxisomal targeting signals of HMG-CoA synthase, MPD, and FPPase were identified, SV(X 5 )QL, SV(X 5 )QL, and KL(X 4 )QE, as a new variation of the PTS-2, respectively. 34) Peroxisomal targeting signals of Acetoacetyl CoA thiolase and IPPase were identified, QKL and HRM, as a new variation of the PTS-1, respectively. 34) However, a peroxisomal targeting signal of HMG-CoA reductase was not identified. Our results indicated that MPD was predominantly located in the cytosol of B16F10 cells, in spite of the fact that MPD contained a peroxisomal targeting signal as a new variation of PTS-2. We previously reported that MPD in rat hepatocytes was not detected in the peroxisomes isolated by cell fractionation. 24) We also reported that a small amount of MPD in rat liver fed on a CP diet existed in the peroxisomes isolated by cell fractionation. 23) From our previous reports, and in this study, it is suggested that a small amount of MPD is transported to peroxisomes from cytosol, when the total amount of MPD is markedly increase by a CP diet. Namely, peroxisomes may serve as urgent isoprenoid synthetic sites when MPD is increased by a marked decrease of cellular cholesterol, although the major site of cholesterol or isoprenoid synthesis is commonly from cytosol to ER, or cytosol, respectively.
In conclusion, we indicated that the expression of MPD in mice is independent of the proliferation of peroxisomes, and MPD is predominantly located in the cytosol of B16F10 cells and does not exist in the peroxisomes. Further studies are necessary to understand the major subcellular location of the enzymes involved in cholesterol synthesis, and the physiological role of MPD. The subcellular distribution of MPD in B16F10 (A) and NRK (B) cells, transferred to the media in the presence (FBSϩ) or absence (FBSϪ) of 10% FBS 24 h prior to the experiment, were examined. B16F10 or NRK cells were incubated in KHM buffer in the presence of digitonin for 5 min at 4°C, and the cells (C; 10 ml) and the medium (M; 10 ml) were analyzed by immunoblotting. Signals of the band were quantified using a Gel-Pro analyzer. Data are the means of three identical experiments, and each varies within 5%.
